Anemia In Chronic Kidney Disease Market: By Treatment, By Product Type, By Dosage Forms, By Route of Administration, By Age, By Gender, By End-User, By Prescription Type drugs, Prescription drugs), By Distribution Channel and By Geography

Anemia In Chronic Kidney Disease Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Iron supplements, Erythropoietin, Vitamin B12 supplements, Folic acid supplements), By Product Type (Tablets, Injectable), By Dosage Forms(Solid, Liquid), By Route of Administration (Oral, Parenteral), By Age(Paediatrics, Adults, Geriatrics), By Gender(Female, Male), By End-User(Hospital pharmacy, Online pharmacy, Retail pharmacy), By Prescription Type (Over-the-Counter (OTC) drugs, Prescription (Rx) drugs), By Distribution Channel (Offline, Online) and By Region

Anemia In Chronic Kidney Disease Market was valued at US$ 873.2 million in 2023 and is anticipated to grow at a CAGR of 5.8% over 2024-2030. Anemia in chronic kidney disease is a common complication of CKD, particularly in the later stages. CKD affects the kidneys' ability to produce erythropoietin, a hormone that stimulates the production of red blood cells. As a result, individuals with CKD may experience a decrease in red blood cell production, leading to anemia. The Anemia in chronic kidney disease market refers to the pharmaceutical and medical products and services aimed at managing anemia in CKD patients.

Treatment options typically include iron supplementation, erythropoiesis-stimulating agents (ESAs), and blood transfusions. ESAs are synthetic versions of erythropoietin and are commonly used to stimulate the production of red blood cells in CKD patients. Iron supplements may also be prescribed, as iron deficiency can exacerbate anemia in CKD. The market for anemia in CKD treatment is significant due to the prevalence of CKD and the impact of anemia on patients' quality of life and overall health. The prevalence of chronic kidney disease can vary significantly in different regions globally. For instance, according to the Centers for Disease Control and Prevention, CKD is common among US adults, around more than 1 in 7 and  4% of US adults are estimated to have chronic kidney disease in 2021. Moreover, Pharmaceutical companies develop and market drugs targeting anemia in CKD patients, and medical devices for blood testing and monitoring are also part of the market. For instance, Akebia Therapeutics launched Auryxia (Ferric Citrate) for the treatment of chronic kidney disease.

Anemia In Chronic Kidney Disease Market Key Developments:
  • In October 2020, the Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho memorial hospital Kaohsiung, Taiwan under the sponsorship of Panion & BF Biotech Inc. doing a study on PBF-1681 (Ferric Citrate) for the treatment of iron deficiency anemia in patients with chronic kidney diseases.

Anemia In Chronic Kidney Disease Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Anemia In Chronic Kidney Disease Market Dynamics

Anemia in Chronic Kidney Disease (CKD) is a significant market driven by several key factors. The growing prevalence of CKD globally is a major growth driver, as anemia often accompanies advanced CKD stages. Rising awareness among healthcare professionals and patients regarding the importance of early detection and management of anemia further propels the market growth. The development of innovative erythropoiesis-stimulating agents (ESAs) and iron therapies, along with ongoing research and clinical trials, presents opportunities for market expansion. Moreover, the increasing elderly population, who are more prone to CKD and anemia, contributes to the market's growth. Additionally, the demand for cost-effective and efficient anemia management solutions, especially in developing regions, creates a favorable environment for market players. Overall, the Anemia in Chronic Kidney Disease Market holds promising prospects due to these growth drivers and opportunities.

Anemia In Chronic Kidney Disease Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 873.2 million

Market CAGR

5.8%

By Treatment

  • Iron supplements
  • Erythropoietin or erythrocyte-stimulating agents
  • Vitamin B12 supplements
  • Folic acid supplements

By Product Type

  •  Tablets
  •  Injectable

By Dosage Forms

  • Solid
  • Liquid

By Route of Administration

  • Oral
  • Parenteral

By Age

  • Pediatrics
  • Adults
  • Geriatrics

By End User

  • Hospital pharmacy
  • Online Pharmacy
  • Retail pharmacy

Key Features of the Report

  • The anemia in chronic kidney disease market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

The Anemia in chronic kidney disease market was valued at US$ 873.2 million in 2022 and is expected to grow at 5.8% CAGR over the forecast period 2023 – 2029.

Key opportunities for the anemia in chronic kidney disease market include Technological advancements and an increase in approval of drugs for the treatment of renal anemia, improved healthcare facilities, and government initiatives in spreading awareness about the symptoms and the available treatment for renal anemia, also increase in healthcare investment day by day will witness lucrative growth opportunities in the forecast period.

Key trends in the Anemia in Chronic Kidney Disease market include the development of novel erythropoiesis-stimulating agents (ESAs), increasing focus on personalized medicine approaches, and the adoption of telemedicine for remote patient monitoring and care.

Vifor Pharma, Sandoz International GmbH, Contract Pharmacal Corp., Akebia Therapeutics Inc., Amgen Inc., Rockwell Medical Inc., Covis Pharma GmbH, and Hoffmann-La Roche Ltd. are prominent companies operating in the field of Anemia In Chronic Kidney Disease market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Anemia In Chronic Kidney Disease Market Introduction 
2.1.Global Anemia In Chronic Kidney Disease Market  - Taxonomy
2.2.Global Anemia In Chronic Kidney Disease Market  - Definitions
2.2.1.Treatment
2.2.2.Product Type
2.2.3.Dosage Forms
2.2.4.Route of Administration
2.2.5.Region
3.Global Anemia In Chronic Kidney Disease Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Anemia In Chronic Kidney Disease Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Anemia In Chronic Kidney Disease Market  By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Iron supplements
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Erythropoietin or erythrocyte-stimulating agents
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Vitamin B12 supplements
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Folic acid supplements
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Anemia In Chronic Kidney Disease Market  By Product Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Tablets
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2.  Injectable
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Anemia In Chronic Kidney Disease Market  By Dosage Forms, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Solid
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Liquid
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Anemia In Chronic Kidney Disease Market  By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Oral
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Parenteral
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
9.Global Anemia In Chronic Kidney Disease Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Iron supplements
10.1.2.Erythropoietin or erythrocyte-stimulating agents
10.1.3.Vitamin B12 supplements
10.1.4.Folic acid supplements
10.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Tablets
10.2.2. Injectable
10.3.  Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Solid
10.3.2.Liquid
10.4.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Oral
10.4.2.Parenteral
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Iron supplements
11.1.2.Erythropoietin or erythrocyte-stimulating agents
11.1.3.Vitamin B12 supplements
11.1.4.Folic acid supplements
11.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Tablets
11.2.2. Injectable
11.3.  Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Solid
11.3.2.Liquid
11.4.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Oral
11.4.2.Parenteral
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Iron supplements
12.1.2.Erythropoietin or erythrocyte-stimulating agents
12.1.3.Vitamin B12 supplements
12.1.4.Folic acid supplements
12.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Tablets
12.2.2. Injectable
12.3.  Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Solid
12.3.2.Liquid
12.4.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Oral
12.4.2.Parenteral
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Iron supplements
13.1.2.Erythropoietin or erythrocyte-stimulating agents
13.1.3.Vitamin B12 supplements
13.1.4.Folic acid supplements
13.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Tablets
13.2.2. Injectable
13.3.  Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Solid
13.3.2.Liquid
13.4.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Oral
13.4.2.Parenteral
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Anemia In Chronic Kidney Disease Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Treatment Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Iron supplements
14.1.2.Erythropoietin or erythrocyte-stimulating agents
14.1.3.Vitamin B12 supplements
14.1.4.Folic acid supplements
14.2.  Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Tablets
14.2.2. Injectable
14.3.  Dosage Forms Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Solid
14.3.2.Liquid
14.4.  Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Oral
14.4.2.Parenteral
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1. Vifor Pharma
15.2.2.Sandoz International GmbH
15.2.3.Contract Pharmacal Corp.
15.2.4.Akebia Therapeutics Inc.
15.2.5.Amgen Inc.
15.2.6.Rockwell Medical Inc.
15.2.7.Covis Pharma GmbH
15.2.8.Hoffmann-La Roche Ltd
15.2.9.Pfizer Inc.
15.2.10.Novartis AG
15.2.11.Johnson & Johnson
15.2.12.Teva Pharmaceutical Industries Ltd.
16. Research Methodology 
17. Appendix and Abbreviations 

Key Market Players

  •  Vifor Pharma
  • Sandoz International GmbH
  • Contract Pharmacal Corp.
  • Akebia Therapeutics Inc.
  • Amgen Inc.
  • Rockwell Medical Inc.
  • Covis Pharma GmbH
  • Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Novartis AG
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.

Related Industry Reports